Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gordon J Freeman

Showing results (111-120 of 348) with videos related to

Pageof 35
Sort By:
The American Journal of Surgical Pathology|July 16, 2014
Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gainMin Shi, Margaretha G M Roemer, Bjoern Chapuy, et al.
Plos One|April 18, 2013
CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survivalFrancesca D'Addio, Takuya Ueno, Michael Clarkson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 22, 2011
Pillars article: CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994. 1: 405-413Theresa L Walunas, Deborah J Lenschow, Christina Y Bakker, et al.
Journal of Virology|July 17, 2009
Upregulation of interleukin 7 receptor alpha and programmed death 1 marks an epitope-specific CD8+ T-cell response that disappears following primary Epstein-Barr virus infectionDelphine Sauce, Martin Larsen, Rachel J M Abbott, et al.
European Journal of Immunology|February 22, 2002
PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2LauraL Carter, Lynette A Fouser, Jason Jussif, et al.
Cell Metabolism|July 12, 2022
Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8<sup>+</sup> T cellsIlaria Elia, Jared H Rowe, Sheila Johnson, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 15, 2018
Role of PD-1 during effector CD8 T cell differentiationEunseon Ahn, Koichi Araki, Masao Hashimoto, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 18, 2012
Cell-intrinsic abrogation of TGF-β signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancerCassie K Chou, Andrea Schietinger, H Denny Liggitt, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 4, 2010
Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infectionHyun-Tak Jin, Ana C Anderson, Wendy G Tan, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|March 12, 2011
Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammationDe-xiu Bu, Margarite Tarrio, Elena Maganto-Garcia, et al.
Pageof 35

Showing results (111-120 of 348) with videos related to

Sort By:
Pageof 35
The American Journal of Surgical Pathology|July 16, 2014
Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gainMin Shi, Margaretha G M Roemer, Bjoern Chapuy, et al.
Plos One|April 18, 2013
CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survivalFrancesca D'Addio, Takuya Ueno, Michael Clarkson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 22, 2011
Pillars article: CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994. 1: 405-413Theresa L Walunas, Deborah J Lenschow, Christina Y Bakker, et al.
Journal of Virology|July 17, 2009
Upregulation of interleukin 7 receptor alpha and programmed death 1 marks an epitope-specific CD8+ T-cell response that disappears following primary Epstein-Barr virus infectionDelphine Sauce, Martin Larsen, Rachel J M Abbott, et al.
European Journal of Immunology|February 22, 2002
PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2LauraL Carter, Lynette A Fouser, Jason Jussif, et al.
Cell Metabolism|July 12, 2022
Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8<sup>+</sup> T cellsIlaria Elia, Jared H Rowe, Sheila Johnson, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 15, 2018
Role of PD-1 during effector CD8 T cell differentiationEunseon Ahn, Koichi Araki, Masao Hashimoto, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 18, 2012
Cell-intrinsic abrogation of TGF-β signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancerCassie K Chou, Andrea Schietinger, H Denny Liggitt, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 4, 2010
Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infectionHyun-Tak Jin, Ana C Anderson, Wendy G Tan, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|March 12, 2011
Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammationDe-xiu Bu, Margarite Tarrio, Elena Maganto-Garcia, et al.
Pageof 35